The agency was originally scheduled to announce its call on Sunday. The company said it hadn’t flagged any issues with the ...
The regulator cited “administrative constraints,” rather than any issue with Moderna’s trial data, for missing a May 12 deadline, the company said.
Just days before its initial deadline, U.S. regulators say they need more time to decide whether or not to approve Moderna's ...
Moderna on Friday said the Food and Drug Administration has postponed an approval decision on its experimental vaccine for ... t expect major delays from here onwards and FDA should be able ...
米バイオテクノロジー大手 モデルナ は10日、呼吸器合胞体ウイルス(RSV)ワクチンの承認可否に関する米食品医薬品局(FDA)の決定が、「事務的な制約」で先送りされたと明らかにした。
The U.S. drug regulator has pushed back its decision on Moderna's respiratory syncytial virus (RSV) vaccine due to ...
Moderna will have to consider that after receiving word that the FDA will not meet a May 12 decision date for its respiratory syncytial virus (RSV) vaccine candidate. The vaccine maker said Friday ...
US regulators’ decision on whether to approve Moderna Inc.’s vaccine for RSV has been delayed due to ... get its second product to market. The FDA hasn’t informed Moderna of any issues ...
its investigational respiratory syncytial virus or RSV vaccine, will be delayed. In pre-market activity on the Nasdaq, Moderna shares were losing around 2.3 percent to trade at $119.91. The FDA ...
Moderna (NASDAQ:MRNA) shares are down just over 1% in early Friday trading after the company said the FDA ... RSV vaccine due to "administrative constraints." However, they remain on track for a ...